Abstract
THE OCCURRENCE OF liver injury in patients receiving monamine oxidase inhibiting drugs of the hydrazine group has been well documented.<sup>1</sup>Similar reactions have not been reported with the nonhydrazine monamine oxidase inhibiting drug, tranylcypromine sulfate.<sup>2</sup>In a patient receiving this drug liver injury developed. After recovery the patient exhibited recurrent symptoms and abnormal laboratory values when given a challenge dose of the drug. <h3>Report of a Case</h3> Since 1958 a 49-year-old housewife had been seen intermittently in the psychiatric clinic for involutional depression. On May 8, 1962, tranylcypromine, 20 mg daily, was prescribed. At a return visit six weeks later, the patient complained of weakness and malaise of recent onset. The significance of these symptoms was not appreciated and the dosage of tranylcypromine was increased to 30 mg daily. One week later the patient returned, complaining of nausea, diarrhea, and anorexia. Dark urine, light stools, jaundice, and epigastric
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
